Marine-derived Compounds
Total Trials
97
As Lead Sponsor
48
As Collaborator
49
Total Enrollment
12,036
NCT00027508
Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
Phase: Phase 2
Role: Lead Sponsor
Start: Jul 31, 2001
Completion: Feb 28, 2002
NCT00147212
ET 743 (Yondelis) in Men With Advanced Prostate Cancer
Role: Collaborator
Start: Jun 30, 2002
Completion: Apr 30, 2008
NCT00050440
Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
Start: Jul 31, 2002
Completion: Jul 31, 2004
NCT00050414
A Study of Trabectedin in Patients With Advanced Ovarian Cancer
Start: Oct 31, 2002
Completion: Sep 30, 2005
NCT00050427
A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer
Start: Dec 31, 2002
Completion: Dec 31, 2006
NCT00060944
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
Start: May 31, 2003
Completion: May 31, 2008
NCT00072670
A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer
Start: Jan 31, 2004
Completion: Nov 30, 2008
NCT00884286
Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
Start: Dec 31, 2004
Completion: Jun 30, 2010
NCT00229203
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
Start: Feb 28, 2005
Completion: Aug 31, 2008
NCT00780975
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
Completion: Mar 31, 2008
NCT00102609
A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma
Phase: Phase 1
Start: Apr 30, 2005
Completion: Oct 31, 2007
NCT00113607
An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
Phase: Phase 3
Completion: Nov 30, 2010
NCT00942591
Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b
Start: May 31, 2005
Completion: May 31, 2009
NCT00404521
A Phase I Study of PM02734 in Subjects With Advanced Malignant Solid Tumors
Start: Aug 31, 2005
Completion: May 31, 2011
NCT00359294
A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma
Start: May 31, 2006
Completion: Sep 30, 2008
NCT01111656
Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b
Start: Mar 31, 2007
Completion: Apr 30, 2010
NCT00579501
Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
Start: Apr 30, 2007
Completion: Jan 31, 2010
NCT00580112
An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer
Start: Jun 30, 2007
Completion: Aug 31, 2011
NCT00780143
Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia
Phase: Phase 1/2
Start: Nov 30, 2007
Completion: Jun 30, 2009
NCT00748202
Berinert P Study of Subcutaneous Versus Intravenous Administration
Start: Sep 30, 2008
Completion: Dec 31, 2010
NCT00786838
A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram
Start: Oct 31, 2008
Completion: Dec 31, 2009
NCT00796120
An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)
Start: Nov 30, 2008
Completion: Aug 31, 2014
NCT00788099
Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas
Start: Dec 31, 2008
Completion: Jun 30, 2011
NCT00884845
Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
Start: Jan 31, 2009
NCT00877474
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors
Start: Mar 31, 2009
NCT00900562
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Start: Aug 31, 2009
Completion: Sep 30, 2011
NCT02249702
Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma
Start: Apr 30, 2010
Completion: Apr 30, 2017
NCT01102426
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Start: Jun 30, 2010
Completion: Nov 30, 2017
NCT01149681
Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
Start: Jul 31, 2010
Completion: Feb 28, 2011
NCT01222767
Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
Start: Dec 31, 2010
Completion: Apr 30, 2012
NCT01299506
Study in Patients With Advanced Soft Tissue Sarcoma (STS) After Failure of Anthracyclines and/or Ifosfamide
Phase: N/A
Completion: Apr 30, 2014
NCT01273493
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
NCT01299636
Study of PM060184 in Patients With Advanced Solid Tumors
Start: Jan 31, 2011
Completion: Aug 31, 2015
NCT01267084
A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies
Start: Feb 28, 2011
Completion: Nov 30, 2012
NCT01970540
Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
Start: May 25, 2011
Completion: Aug 9, 2017
NCT01314599
Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome
Start: May 31, 2011
Completion: Jul 31, 2015
NCT01970553
Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors
Completion: Oct 31, 2013
NCT01343277
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
Start: Jun 30, 2011
Completion: Apr 30, 2016
NCT01379989
INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer
Completion: Dec 17, 2020
NCT01405391
Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks
Start: Nov 30, 2011
Completion: Jan 31, 2016
NCT01876043
Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial
Start: Feb 29, 2012
Completion: Apr 30, 2015
NCT01525589
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Start: Jun 13, 2012
Completion: Oct 31, 2018
NCT02210364
Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).
Start: Apr 30, 2013
Completion: Oct 31, 2016
NCT02394015
Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC
Start: May 6, 2013
Completion: Dec 31, 2017
NCT01735071
Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer
Start: Jul 31, 2013
Completion: Mar 18, 2018
NCT02194231
ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)
Completion: Dec 12, 2019
NCT01951157
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
Start: Sep 11, 2013
Completion: Nov 30, 2016
NCT01831089
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Start: Sep 30, 2013
Completion: Jul 31, 2016
NCT01846611
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Start: Oct 16, 2013
Completion: Nov 16, 2018
NCT02100657
Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma
Start: Jun 30, 2014
Completion: Jun 30, 2018
NCT02163720
Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)
Start: Jul 10, 2014
Completion: Sep 18, 2018
NCT02398058
Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)
Start: Jul 20, 2014
Completion: Dec 1, 2019
NCT01980667
Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors
Start: Jul 30, 2014
Completion: Jan 5, 2017
NCT02204111
Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma
Start: Sep 30, 2014
Completion: Sep 30, 2017
NCT02533674
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
Start: Dec 12, 2014
Completion: Jul 11, 2019
NCT02421588
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Start: May 31, 2015
Completion: Oct 12, 2018
NCT02825420
Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients
Start: Jul 28, 2015
Completion: Sep 18, 2019
NCT02684318
Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors
Start: Jul 31, 2015
Completion: Oct 31, 2019
NCT02451007
Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors
Start: Aug 12, 2015
Completion: Aug 19, 2016
NCT02454972
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Start: Aug 25, 2015
Completion: Sep 18, 2020
NCT02448537
A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
Start: Aug 31, 2015
Completion: Apr 1, 2019
NCT02805725
Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide
Start: Dec 31, 2015
Completion: Dec 31, 2021
NCT02611024
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Start: May 6, 2016
Completion: Jul 1, 2025
NCT02809339
Improving Quality of Care for Patients With Recurrent Ovarian Cancer
Start: Jul 31, 2016
NCT02566993
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
Start: Aug 30, 2016
Completion: Feb 24, 2020
NCT03070964
A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
Start: Oct 25, 2016
Completion: Jul 31, 2018
NCT03284320
Retrospective Study in Sarcoma Patients
Start: Apr 18, 2017
Completion: Nov 1, 2021
NCT03085225
Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
Start: May 5, 2017
Completion: Jan 4, 2022
NCT03117361
Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
Start: May 8, 2017
Completion: Jul 30, 2018
NCT05076396
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
Start: Sep 6, 2017
Completion: Aug 13, 2025
NCT02929394
Trabectedin Maintenance Post 1st-line in STS
Start: Nov 7, 2017
Completion: Jun 5, 2020
NCT03427268
Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
Start: Jan 16, 2018
Completion: Feb 11, 2019
NCT03164980
QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer
Phase: Phase 4
Start: Feb 1, 2018
Completion: Aug 8, 2023
NCT03590210
Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas
Start: Jun 8, 2018
Completion: Feb 12, 2022
NCT03127215
Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors
Start: Oct 25, 2018
Completion: Dec 19, 2023
NCT03773510
Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin
Start: Feb 28, 2019
Completion: Oct 1, 2025
NCT04382066
Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
Start: May 12, 2020
Completion: Nov 26, 2020
NCT03838744
Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
Start: May 20, 2020
Completion: Nov 29, 2024
NCT04358237
Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.
Start: Sep 21, 2020
Completion: May 20, 2025
NCT05063318
Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors
Start: Oct 7, 2020
Completion: Apr 21, 2022
NCT05072106
Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors
Start: Jan 14, 2021
Completion: Jan 18, 2022
NCT05101265
Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment
Start: Mar 9, 2021
Completion: Jun 1, 2025
NCT04784559
Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
Start: Jun 4, 2021
Completion: Mar 1, 2023
NCT04305548
Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
Start: Sep 14, 2021
Completion: Dec 1, 2025
NCT04383119
Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma
Start: Oct 29, 2021
Completion: Dec 31, 2025
NCT05121740
Extension Study in a Cohort of Adult Patients With COVID-19 Infection
Start: Jan 25, 2022
Completion: Mar 16, 2022
NCT05285033
RW Effectiveness of Lurbinectedin in Extensive Stage SCLC
Start: Apr 1, 2022
Completion: Dec 15, 2022
NCT05153239
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
Start: Jul 22, 2022
Completion: Apr 30, 2026
NCT05835609
PM534 Administered Intravenously to Patients With Advanced Solid Tumors
Start: Dec 23, 2022
Completion: Oct 31, 2026
NCT05705167
Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA)
Start: Apr 19, 2023
Completion: Apr 19, 2024
NCT05841563
Clinical Trial of PM54 in Advanced Solid Tumors Patients.
Start: Apr 28, 2023
Completion: Apr 30, 2027
NCT06088290
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
Start: Sep 21, 2023
Completion: Aug 30, 2029
NCT05572476
Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer
Start: Oct 31, 2023
Completion: May 31, 2024
NCT06050434
Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients
Completion: Jul 30, 2024
NCT06524583
Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
Start: Jan 27, 2025
Completion: Dec 31, 2030
NCT06766825
Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post-COVID-19 Condition (PCC)
Start: Feb 7, 2025
Completion: Jun 1, 2026
Loading map...